Fluidigm Introduces the First Complete Sample-to-Answer Solution for Deep Immune Profiling by Mass Cytometry
The new standard in immune profiling for advancing translational and clinical research of immune-mediated diseases SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the introduction of the Maxpar® Direct™ Immune Profiling System. Setting the new standard in immune... Read more